Semaglutide beneficial for people with obesity, knee osteoarthritis

For individuals with obesity and knee osteoarthritis, once-weekly semaglutide yields greater reductions in body weight and pain related to knee osteoarthritis than placebo, according to a study published in the Oct. 31 issue of the New England Journal of Medicine.

Henning Bliddal, M.D., from the Copenhagen University Hospital at Bispebjerg and Frederiksberg in Denmark, and colleagues conducted a 68-week trial at 61 sites in 11 countries. Four hundred seven participants with obesity and a clinical and radiologic diagnosis of moderate knee osteoarthritis with at least moderate pain were randomly assigned to receive once-weekly subcutaneous semaglutide or placebo in a 2:1 ratio in addition to counseling on physical activity and a reduced-calorie diet.

The researchers found that from baseline to week 68, the mean change in body weight was −13.7 and −3.2 percent with semaglutide and placebo, respectively. At week 68, the mean change in the Western Ontario and McMaster Universities Osteoarthritis Index pain score was −41.7 and −27.5 points with semaglutide and placebo, respectively.

Greater improvement in the 36-Item Short Form Health Survey physical-function score was seen for participants in the semaglutide group versus placebo group (mean change, 12.0 versus 6.5 points). The two groups had a similar incidence of serious adverse events.

“The findings support the use of once-weekly subcutaneous semaglutide at a dose of 2.4 mg for weight management and treatment of pain in persons with obesity and moderate-to-severe pain due to knee osteoarthritis,” the authors write.

The study was funded by Novo Nordisk, the manufacturer of semaglutide.

More information:
Henning Bliddal et al, Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis, New England Journal of Medicine (2024). DOI: 10.1056/NEJMoa2403664

David T. Felson, Glucagon-Like Peptide-1 Receptor Agonists and Osteoarthritis, New England Journal of Medicine (2024). DOI: 10.1056/NEJMe2409972

Copyright © 2024 HealthDay. All rights reserved.

Citation:
Semaglutide beneficial for people with obesity, knee osteoarthritis (2024, October 31)
retrieved 31 October 2024
from https://medicalxpress.com/news/2024-10-semaglutide-beneficial-people-obesity-knee.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Before you post, please prove you are sentient.

What is the outer covering of a tree?

Explore More

Body weight is an important health factor in pregnancy — regardless of country of birth

Overweight is a major contributor to complications during pregnancy and childbirth — this applies to both women born in Sweden and women who have moved here, something that has not

Abnormal electrolyte levels in people with eating disorders may increase risk of death, poor health outcomes

Infographic. Credit: ICES A study published in The Lancet Psychiatry found that 32% of individuals with an eating disorder had abnormal electrolyte levels, which were associated with a higher risk

Metabolic and bariatric surgery safe and effective for patients with severe obesity, study finds

A team of researchers led by Pennington Biomedical Research Center’s Dr. Florina Corpodean confirmed through a data analysis that metabolic and bariatric surgery is largely safe and effective for patients